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a  b  s  t  r  a  c  t
Constipation  appears  in the  2nd  and  3rd  trimester  of pregnancy,  while  nausea  is the  strongest  in  the  1st
trimester.  This  review  summarizes  the  applicability  of herbal  laxatives  and  antiemetics  in pregnancy.
A  human  study  has  shown  that  ﬂax oil as laxative  is  safe  from  2nd  trimester.  Human  data  is  not
available  about  the  rhubarb,  but  animal  studies  reveal  that  its emodin  content  induces  fetal  abnormalities.
Fenugreek  induces  teratogenic  malformation  both  in  human  and  animals.  Senna  seed is  proved  as  a  safe
laxative  in  pregnancy.  The  antiemetic  ginger  is safe  during  1st  trimester,  but  it reduces  the  gestational
period  when  applied  from  the  2nd  trimester.  Cannabis  induces  fetal  neurological  disorders  while  fennel
can  shorten  the  gestational  age.
There is herbal  alternative  for laxative  therapy  (senna)  for  the  whole  length  of  pregnancy,  but  nausea
and  vomiting  might  be  reduced  by herbal  medicine  (ginger)  safely  in  the  1st trimester,  only.
© 2017 Elsevier  Inc.  All  rights  reserved.
1. Introduction
Several maternal symptoms may  cause difﬁculties during preg-
nancy. Even milder disorders may  challenge the therapy because
of the risk of teratogenic or embryotoxic consequences. A Dutch
population-based cohort study found that 5% of pregnant women
receive potentially teratogenic drugs during pregnancy [1]. The
majority of pregnant women try to avoid pharmacotherapy, and
have better conﬁdence towards alternative therapies, especially in
the last trimester of pregnancy. According to a survey, the most
common alternative remedies are the oral herbal products among
women in the third trimester [2], although their safety is not always
proved. Additionally, there are the different kinds of oriental herbal
shops among the major sources of herbal products, where the
advertisements and the provided information do not always com-
ply with the regulations [3].
Constipation, nausea and vomiting are among the most frequent
complaints in pregnancy.
Constipation  mainly appears in the second and third trimester,
its prevalence is around 40% during pregnancy [4]. The most com-
mon  consequences of long term constipation are hemorrhoids and
anal ﬁssures [5]. Several factors can be mentioned as potential rea-
sons for the symptom: slower gastrointestinal (GI) transit time,
higher plasma level of progesterone and mechanical obstruction
[6].
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The global prevalence of nausea is about 70%, while vomit-
ing occurs in half of pregnancies [7]. The high plasma level of
human chorionic gonadotropin and the increased placental mass
are among the main factors that increase the severity of vomiting
and may  lead to hyperemesis gravidarum. This condition is one
of the most frequent reasons for the hospitalization and the elec-
trolyte therapy of pregnant women  [8]. The major problem is that
nausea and vomiting appear in the ﬁrst trimester, when any type
of pharmacological or herbal treatment might have a teratogenic
risk and may  cause fear in mothers [9].
The aim of this review is to summarize the risks of well-known
herbal laxatives and antiemetics in pregnancy by presenting pre-
clinical and clinical evidence.
2.  Search strategy
A  systematic literature search for toxicity of herbal laxatives
and antiemetics during pregnancy in PubMed, Google Scholar and
Web  of Knowledge was performed (1980–2016). Search words
were “ herbal laxatives”, “herbal antiemetics”, followed by the
“toxic”, “adverse effects”, and “gestation”, or “herbal medicines”
combined with “prenatal”, “postnatal”, “during pregnancy”, “ter-
atogenic effect”, “safety”, and “ harm” respectively. Search was
limited to the English language. Cohort studies, reviews, Meta-
analyses and randomized-controlled trials were selected. Human
studies have been included in the review when the number of par-
ticipants was  higher than 600 and the study interval was  at least 4
years. Animal studies have been included when human data were
http://dx.doi.org/10.1016/j.reprotox.2017.06.041
0890-6238/© 2017 Elsevier Inc. All rights reserved.
154 R. Samavati et al. / Reproductive Toxicology 72 (2017) 153–158
not available or few. The total number of identiﬁed papers is not
recorded, but 76 articles were reviewed in this publication.
3.  Herbal laxatives in pregnancy
3.1. Rhubarb (Rheum emodi)
Rhubarb contains emodin, a purgative resin (6-methyl-1,3,8-
trihydroxyanthraquinone). The cytotoxic effects of emodin were
investigated on mouse embryos at the blastocyst stage, followed by
embryonic attachment and outgrowth in vitro and in vivo implanta-
tion by embryo transfer [10]. After the treatment of blastocysts with
25–75 M emodin, they observed signiﬁcantly increased apoptosis
and a corresponding decrease in total cell number. In compari-
son with the control group, blastocysts pretreated with emodin
showed a signiﬁcantly lower implantation success rate. Further-
more, in vitro treatment with 25–75 M emodin was  associated
with decreased fetal weight and increased resorption of post-
implantation embryos. Through an in vivo mouse model, they
showed that consumption of drinking water contaminated with
emodin can lead to apoptosis and reduced cell proliferation, and
inhibited early embryonic development in the blastocyst stage.
In  another investigation, the developmental toxicity of emodin
was evaluated in mice and rats [11]. They selected low dose of
425 ppm/day emodin for rats according to (National Toxicology
Program, 2002a), because it was not likely to cause maternal or
fetal toxicity. In this study the middle dose was 850 ppm/day
and high dose of 1700 ppm/day was expected to cause signif-
icant maternal toxicity when it was administrated during the
embryo/fetal development, and possibly reduced fetal body weight.
Doses were applied through NIH-07 ground rodent diet from the
gestational day 6 until the day 20. Mice were treated with low
dose 600 ppm/day of emodin due to same reason as described for
rats. Chosen dose was based on a signiﬁcant decrease in mater-
nal weight gain from pregnancy days 15–17 during a screening
study (National Toxicology Program, 2000) at the low dose of
750 ppm (115 mg  emodin/kg/kday). In this case the middle dose
was 2500 ppm/day. The selected high dose 6000 ppm/day was
applied during embryo/fetal development. Administration route
was similar to rats and started from the pregnancy day 6 until
day 17. The treatments outcome did not show any maternal death,
but maternal body weight, weight gain during treatment, and cor-
rected weight gain were observed in a decreasing pattern in the
rats. Moreover, these symptoms appeared more signiﬁcantly dur-
ing treatment at the high dose. In mice, maternal body weight and
weight gain were decreased at the high dose as well. Other evalu-
ated parameters such as fetal sex ratio, prenatal mortality, live litter
size and morphological development were unaffected in both rats
and mice. On the other hand, they observed at the high dose that
rat average fetal body weight per litter was unaffected, while it was
signiﬁcantly reduced in mice.
Controlled human data is not available about the emodin effects
during pregnancy. In males, however, it inhibits the human sperm
function [12].
3.2.  Fenugreek (Trigonella foenum graecum)
Fenugreek is cultivated worldwide and it is one of the oldest
traditional medicinal plants. Traditionally, it is known as a cooking
herb but the seeds are also known to settle the stomach and relieve
constipation. Toxicological animal studies evaluated the acute tox-
icity of the fenugreek leaves and seeds and have shown that the
teratogenic dose of fenugreek can differ between species and sexes
[13].
In rat treated by fenugreek seed powder during the ﬁrst ten
days of pregnancy (175 mg/kg/day), anomalies were reported [14]
including inverted/averted claw (18% and 21%), shoulder joint
defect, tail kinking, non-ossiﬁed skull bones and neural pore (18%),
clubbing of hind limb (9%), and enlarged neural canal (6%). In
an acute treatment study during the organogenesis period (day
10 of gestation), a single intraperitoneal dose of fenugreek aque-
ous extract (0.8, 1.6 and 3.2 g/kg) increased the mortality rate
in embryos in a dose dependent manner [13]. Another separate
study also reported that fenugreek decoction (0.8, 1.6, and 3.2 g/kg),
administrated intraperitoneally to rats, decreased the fetal ear to
ear diameter and increased the fetal mortality rate [15]. Addi-
tionally, single intraperitoneal injection of fenugreek leaf aqueous
extract (3.2 g/kg) in the day 10 of the pregnancy (the time of organo-
genesis initiation and development of limb bud) can cause severe
adverse alterations in the fetus, such as disorder in developing the
long bone of the hind limb [16].
Studies on mice showed that lyophilized fenugreek seeds aque-
ous extract supplementation (500 and 1000 mg/  kg/day) during
the whole gestation period decreases the litter size, increases pup
mortality, reduces body weights (body weight was measured at
postnatal days 1, 7, 14, 21 and 28), and induces malformations (cleft
palate formation and a bump on head in newborns), growth retar-
dation, altered neurobehavioral in the post weaning period [17].
Body weight at birth time has shown 27% reduction in the case
of 1000 mg/kg treated mothers and 32% in the 500 mg/kg treated
group compared with control puppies. Brain weight reduced 10%
in both treated groups. Similar consequences have been proved in
rabbits: the diets containing 30% fenugreek seeds caused a signiﬁ-
cant reduction in fetal development due to the reductions of both
fetal and placental weights and litter size at gestation day 20 [18].
Prenatal  exposure to the aqueous extract of fenugreek seeds
(500 or 1000 mg/kg/day) can also induce a signiﬁcant decrease in
the locomotor activity in both male and female mice, suggesting
that aqueous extract of fenugreek seeds induces a depressive effect
in the offspring [17].
In  humans, congenital malformation cases such as hydro-
cephalus, anencephaly, cleft palate and spina biﬁda were reported
among women who  consumed fenugreek seeds during gestation
[13]. Interestingly, there are case reports of neonates being born
with a peculiar odor following maternal consumption of fenugreek
just before delivery, which supports the transplacental passage of
fenugreek compounds to the fetus [13,19].
It emerges from this evidence that fetal malformations, growth
disturbance and disordered function might be the consequences
of fenugreek seeds containing an estrogenic feature agent that
perturbs the endometrial lining system and interferes with fetal
growth. Therefore more investigation is required to clarify the fenu-
greek teratogenic compound(s).
3.3.  Flaxseed (Linum usitatissimum)
Flax  is also known as common ﬂax or linseed. It contains various
dietary components such as a high content of n-3 fatty acids, ﬁbers
and other compounds [20]. Flax is the main herbal source of sec-
oisolariresinol diglucoside which is precursor of enterolacton and
entrodiol [21]. These lignans have similar structure to 17-estradiol
that could express estrogen agonist or antiestrogen like effects
depending on dose, stage of development and duration of treatment
[22–24]. Moreover, it also contains a detectable amount of cad-
mium,  which can activate the estrogen receptor (ER). It is revealed
that estrogenic exposures at the early life stages can modify suscep-
tibility to developing breast cancer. The maternal dietary intake of
5% or 10% ﬂaxseed during pregnancy or lactation (between postpar-
tum days 5 and 25) might affect 7,12 dimethylbenz[a]anthracene
(DMBA)-induced mammary tumorigenesis in the rat offspring. It is
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proclaimed that both in utero and postnatal 5% and 10% ﬂaxseed
exposures can shorten mammary tumor latency, and 10% ﬂaxseed
exposure increased tumor multiplicity, compared to the controls
[25].
Additionally, in 8-week-old rats, ﬂaxseed exposure (10% in
utero) increased lobular ER- protein levels, and both in utero
and postnatal ﬂaxseed exposures dose-dependently decreased ER-
 protein levels in the terminal end buds (TEBs) lobules and ducts.
Exposures to ﬂaxseed cannot alter the number of TEBs or affect cell
proliferation within the epithelial structures. In the other group of
immature rats that were fed 5% defatted ﬂaxseed diet for a week (7
days), exposure to cadmium through the diet was  six-fold higher
than allowed for humans by the World Health Organization, and
cadmium signiﬁcantly accumulated in the liver and kidneys of the
rats. It remains to be determined whether the increased mam-
mary cancer in rats exposed to ﬂaxseed through a maternal diet
in utero or lactation was caused by cadmium present in ﬂaxseed,
and whether the reduced mammary ER- content was causally
connected to the increased risk of mammary cancer among the
offspring. The preclinical study of Collins et al. shown that high
ﬂaxseed (up to 40%) and defatted ﬂaxseed (up to 26%) content of
the meal had not any apparent action on pregnancy in rats [26].
Only one human study is available about the effect of ﬂaxseed in
pregnancy. Flax oil capsule were given between gestational weeks
12 and 27 for almost 400 pregnant women, but no difference was
found in timing of spontaneous delivery. This study suggests that
ﬂaxseed oil is not harmful in the 2nd and 3rd trimester of preg-
nancy, although further investigations are necessary to get more
evidence for the safety of ﬂax oil consumption during pregnancy
[48].
3.4. Senna seed (Cassia occidentalis)
Senna occidentalis, also known as septicweed, coffee senna and
coffeeweed is a pantropical traditional medical plant. The seeds
are roasted, brewed and served as tea to treat hemorrhoids, gout,
rheumatism, diabetes, and it has diuretic and laxative effects as
well. It was used as an antidote for several types of poison and as a
potent abortifacient [27].
In  an animal model, the possible toxicity effect of oral sub-acute
administration of senna during pregnancy has been investigated in
female Wistar rats [27]. They were treated in the period of organo-
genesis during pregnancy (pregnancy days 1–14), at doses 250
and 500 mg/kg. After euthanasia of the animals, the reproductive
parameters were evaluated on the 20th day of pregnancy. No statis-
tically signiﬁcant differences were found between the control and
the treated groups in fetal, placental and ovarian weights; in the
number of implantation and resorption sites; in the number of cor-
pus luteum and in pre- and post-implantation loss rates. However,
the numbers of dead fetuses were increased after doses of 250 and
500 mg/kg of senna.
In goat, it is reported that perinatal exposure (from pregnancy
detection on day 27 after mating until delivery) to senna in different
concentrations (1, 2 and 4% senna seed in the food) can cause fetal
death and resorption of fetuses at higher concentration. Besides
that, one dam from the higher dose treated group had tissue lesions
as vacuolations in hepatocytes and kidneys; also, cardiac muscle
and skeletal necrosis was detected. It can cause lesions in sciatic
nerve cells as well. Therefore it is suggested that 4% of senna seed
in the food of goats is toxic during pregnancy, but lower concen-
trations (1 or 2%) have less toxicity in natal and post-natal body
development [28].
A  human retrospective study (data from 1980 until 1996) in
Hungary showed that, out of 22,843 cases with congenital abnor-
malities (CA), in 506 (2.2%) cases the mothers were treated with
senna, while among 38,151 control newborn infants without CA,
937 (2.5%) were born from mothers who  had senna treatment, and
out of 834 malformed controls with Down syndrome, 26 (3.1%)
cases had mothers with the use of senna. These women used senna
in doses between 10 mg  and 30 mg,  but most of them used 20 mg
daily [29]. They did not ﬁnd a higher risk for 23 different CA groups
after the senna treatment during the second and/or third month of
pregnancy among 260 mothers (i.e. in the critical period of most
major CAs, compared with their 500 matched controls). They also
reported that pregnancy duration was a bit longer (0.2 week) and
the rate of preterm birth was lower (6.6% vs. 9.2%) as compared
with mothers who  were not exposed to senna.
In a separate evaluation they revealed, if severe constipation
in pregnant women  requires laxative drug treatment, senna can
be administered safely because they did not ﬁnd a high rate of CA
among the offspring of pregnant women  whose severe constipation
had been treated with senna [30].
4. Herbal antiemetics in pregnancy
4.1. Marijuana (Cannabis sativa)
Cannabis is the most widely used illicit drug amongst pregnant
women with a prevalence of use ranging from 3 to 30% in various
population. It has a strong antiemetic effect; theoretically it might
be used for the treatment of nausea or morning sickness during
pregnancy. However, its safety is more than doubtful. Animal and
human studies were carried out to clarify the toxicity of cannabis
in pregnancy.
In  a study, pregnant mice were exposed (nasal) for 5 min  daily
to cannabis (0.2 g) smoke from gestational day 5.5–17.5 or ﬁltered
air (control). It was  found that 5 min of daily cannabis exposure
can decrease the birthweight, but the litter size was not reduced;
interestingly, even the number of male pups per litter was higher.
Additionally, the weight of wet placenta was increased but fetal
to placental weight ratio was decreased in male fetuses, which
showed a sex-related effect. Exposed females presented reduced
maternal net body weight gain at the end of gestation, despite a
slight increase in their daily food intake compared to the control
group [31].
Another study applying behavioral assays, extracellular ﬁeld
potential recordings and whole-cell patch clamp recordings inves-
tigated the maternal exposure to the CB1 cannabinoid receptor
agonist WIN  55–212–2 (WIN) in rats [32]. Treated pregnant rats
showed a signiﬁcant decrease in the rearing frequency, total dis-
tance moved and mobility of the offspring, but they showed a
signiﬁcant increase in the righting reﬂex time, the grooming fre-
quency and immobility. They also reported a signiﬁcant impair
in neuromotor function. However, the amplitude of population
spikes (PS) recorded from the cerebellar Purkinje cell layer of off-
spring increased following synaptic blockage. Maternal exposure
also deeply affected the intrinsic properties of Purkinje neurons of
offspring. This treatment increased the ﬁring regularity, ﬁring fre-
quency, amplitude of after hyperpolarization, the peak amplitude
of action potential and the ﬁrst spike latency, but on the other hand
it decreased signiﬁcantly the time to peak and duration of action
potentials, the instantaneous ﬁring frequency, the rate of rebound
action potential and the voltage “sag” ratio. Besides these animal
studies, there are several other investigations which revealed the
teratogenic and toxic effect of cannabis exposure during the pre-
natal period in animals [33].
On the other hand, there is some evidence that shows cannabis
use during pregnancy and lactation in humans can cause various
damages to the fetus and newborn babies during breastfeeding.
In  a cohort study, 5588 nulliparous women at 15 ± 1 and
20 ± 1 weeks of pregnancy were investigated [34]. Cases were
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included: 278 preeclampsia, 470 gestational hypertension, 633
small-for-gestational-age, 236 spontaneous preterm births, and
143 gestational diabetes cases, which were compared separately
with 4114 non-cases. Continued maternal marijuana use at 20
weeks of pregnancy was associated with spontaneous preterm
births that were independent of cigarette smoking status and
socioeconomic index. By another evaluation, among 8138 women
in the cohort, 680 (8.4%) of them used marijuana during pregnancy.
Women who used marijuana were younger; had inadequate prena-
tal care; and used tobacco, alcohol, and other drugs as well. Medical
comorbidities did not differ between groups. It was concluded that
marijuana use in pregnancy may  not be an independent risk factor
for poor neonatal outcomes in term pregnancies [35].
There  is a review focused on the cannabis-mediated mater-
nal effects on the central nervous system and sensitization to
late-onset chronic and neuropsychiatric disorders [36]. They did
compare clinical and preclinical experimental studies on the
effects of fetal cannabis exposure until early adulthood as well.
Preclinical experimental models conﬁrmed clinical studies and
revealed that cannabis exposure can evoke signiﬁcant molecu-
lar modiﬁcations to neurodevelopmental programs, which lead to
neurophysiological and behavioral abnormalities. There are more
documents that conﬁrm cannabis can cause signiﬁcant neurobi-
ological and neuropsychiatric consequences on the human fetus
[37]. Analyzing of the birth outcomes data from 24874 women
with cannabis use in a cohort study during 7 years (2000–2006)
at the Mater Mothers’ Hospital in Brisbane/Australia, shown low
birth weight (odds ratio (OR) = 1.7; 95% conﬁdence interval (CI):
1.3–2.2), preterm labor (OR = 1.5; 95% CI: 1.1–1.9), small for
gestational age (OR = 2.2; 95% CI: 1.8–2.7), and more frequent
admission to the neonatal intensive care unit (OR = 2.0; 95% CI:
1.7–2.4) [38]. Similar adverse birth outcomes (low birth weight)
were reported after the maternal cannabis use during pregnancy
[39].
4.2. Fennel (Foeniculum vulgare)
The effects of fennel essential oil (FEO) on the uterine con-
traction and evaluation of lethal dose 50% (LD50) in rat were
studied [40]. It was found that after the administration of differ-
ent doses of FEO (10, 20, 25, 40 and 50 g/ml), the oxytocin (0.1,
1 and 10 mU/ml) – and prostaglandin E2 (5 × 10−5 M)  – induced
contractions were reduced signiﬁcantly. The estimated LD50 was
1326 mg/kg for FEO. Any damage in the vital organs of the dead
animals did not report.
The  teratogenicity of FEO was investigated on the rat embryo
limb buds [41]. The results showed that FEO at a low concentra-
tion (0.93 mg/ml) caused a signiﬁcant reduction in the number of
stained differentiated foci. On the other hand, FEO signiﬁcantly
diminished differentiation at higher doses, however paradoxically
high dose of 3.72 mg/ml  could not cause a signiﬁcant effect. They
did not observe statistical difference in the number of foci between
the control group and the exposed group to the 50 l of ethanol
(as the highest concentration of vehicle) in 1 ml  of culture medium.
They  suggest that the FEO at the applied concentrations may have
a toxic effect on fetal cells, but they did not report any evidence of
teratogenicity.
In a cohort study involving 630 pregnant women, collected data
from mothers revealed that regular consumption of fennel during
pregnancy can lead to shorter gestational age in women compared
to non-users [42].
4.3.  Ginger (Zingiber ofﬁcinale)
Ginger  has been used world-widely against pregnancy-induced
nausea and vomiting during the centuries. However, its safety in
pregnancy is still doubtful and there is a continuous debate on its
application, especially in the ﬁrst trimester.
The effect of ginger, a common morning sickness remedy, on
fetal development in rat was investigated. Ginger produces 6- gin-
gerol, which gives the spicy taste to ginger. 6- gingerol is thought to
be a potential teratogenic due to its effect on some essential embry-
onic developmental processes (i.e. disruption of angiogenesis). It is
conﬁrmed by its capacity to inhibit the proliferation and tube for-
mation of primary cultured human endothelial cells through down
regulation of cyclidin D and also inhibition of tumor growth in mice
by its anti-angiogenic activity [43]. Moreover, it can induce apopto-
sis, DNA mutation, decrease cell migration and motility in a dose
dependent manner, arresting the cell cycle and stop cancer cells
proliferation. Therefore, it can be embryotoxic in the ﬁrst trimester
when ginger might be taken to relieve morning sickness.
In  a preclinical study, 20 or 50 g/L ginger tea were adminis-
tered to rats from pregnancy day 6–15, through their drinking
water. After the sacriﬁce on day 20, no toxic signs were observed
in the mothers. However, the embryonic loss in the treated groups
was double compared to controls. The fetuses that were exposed
to ginger tea were signiﬁcantly heavier than controls; this effect
was more expressed in female fetuses and was not linked with
increased placental size. Treated fetuses also showed advanced
skeletal development [44]. The results suggest that in utero expo-
sure to ginger tea results in increased early embryo loss with
increased growth in surviving fetuses. 630 pregnant women  with
ginger intake were participated in a study for 4 years in an Italian
public hospital. Shorter gestational age and smaller circumference
of the newborn’s skull were observed [42].
Although according to data from 1966 until September 2004,
ginger has been proposed as a safe and efﬁcacious alternative to
conventional antiemetic drugs [45], some opinions suggest that
it would be prudent to avoid using either ginger or its extracted
compounds [46]. On the other hand, the greatest review about the
application of ginger in pregnancy claims that ginger is safe for
nausea and vomiting in the ﬁrst trimester. Even the American Col-
lege of Obstetrician and Gynecologists and the U.K. National Health
Service have accepted ginger as an applicable antiemetic in early
pregnancy [47].
Table 1
Classiﬁcation of herbal laxative and antiemetic according to their safety.
Safety
Therapeutic use Safe to use Use with precaution More evidence is
required,  not
recommended
Forbidden No human data are
available
Laxative  - Senna Flaxseed (2nd and
3rd  trimester)
Fenugreek – - Rhubarb
-Flaxseed (1st
trimester)
Antiemetic  Ginger (1st
trimester)
Fennel, Ginger (2nd
and  3rd trimester)
– -Cannabis –
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5. Conclusion
From ancient times until today herbal medicines had a long
journey from being a medicine at that time to becoming a
healthy remedy source in the 21st century. Regarding all the men-
tioned studies and investigations, contrary to popular belief, herbal
medicines cannot be safe all the time, especially during pregnancy.
A conclusion of gestational safety of herbal laxatives and
antiemetics is shown in Table 1. During pregnancy the majority
of the herbal drugs for constipation can be harmful, especially if
they have been taken in the ﬁrst trimester. Available clinical evi-
dence proves that the only harmless gestational herbal laxative is
senna using even through the whole gestational period. The most
harmful herbal drug which is commonly used by pregnant women
(cannabis) can be teratogenic and embryotoxic even at low doses
and therefore its use as an antiemetic is not recommended. How-
ever, ginger seems to be safe as a gestational antiemetic, but only
in early pregnancy.
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